- Medicine Name: Rolvedon
- Generic Name: Eflapegrastim-xnst
- Dosage Form & Strength: Injection: 13.2 mg/0.6 mL solution
- Manufactured By: Spectrum Pharmaceuticals, Inc.
Rolvedon (eflapegrastim-xnst) is a leukocyte growth factor used to reduce the incidence of infection, as manifested by febrile neutropenia, in adults with non-myeloid malignancies receiving myelosuppressive anti-cancer therapeutic drugs linked with a clinically significant incidence of febrile neutropenia.
Limitations of Use: Rolvedon 13.2 mg/0.6 mL is not for the mobilization of peripheral blood progenitor cells for hematopoietic stem cell transplantation.
Recommended Dosage: The recommended dosage of Rolvedon is a single subcutaneous (SC) injection of 13.2 mg given once per chemotherapy cycle. Administer around 24 hours after cytotoxic chemotherapy. Avoid administering within the period from 2 weeks before to 24 hours after the use of cytotoxic chemo.
All Trademarks and Brands that appear on the website belong to their respective owners and indianpharmanetwork does not lay any claim on them we only provide Information.